Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | CA1 | P00915 | 4/20 | 0.65 |
| ▸ | CA2 | P00918 | 4/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.62 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29118836 | 1.00 | KMT2A (0.71) | KMT2AMEN1MAPTALDH1A1CYP1A2 | |
| SCHEMBL14601685 | 0.91 | MEN1 (0.65) | KMT2AMEN1MAPTALDH1A1CYP1A2 | |
| SCHEMBL11793140 | 0.86 | CA1 (0.85) | KMT2AMEN1MAPTALDH1A1CYP1A2 | |
| SCHEMBL540915 | 0.86 | CA1 (0.85) | KMT2AMEN1MAPTALDH1A1CYP1A2 | |
| SCHEMBL12462888 | 0.85 | HTR6 (0.59) | KMT2AMEN1MAPTALDH1A1CYP1A2 | |
| SCHEMBL7577535 | 0.85 | CA1 (0.65) | KMT2AMEN1MAPTALDH1A1CYP3A4 | |
| SCHEMBL11419365 | 0.84 | RORA (0.74) | KMT2AMEN1MAPTALDH1A1CYP1A2 | |
| SCHEMBL31198191 | 0.83 | UQCRB (0.71) | KMT2AMEN1MAPTCA1CA2 | |
| SCHEMBL20657557 | 0.83 | KMT2A (1.00) | KMT2AMEN1MAPTALDH1A1CYP1A2 | |
| SCHEMBL18031173 | 0.83 | UQCRB (0.71) | KMT2AMEN1MAPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066410-A1 | INHIBITORS OF BROMODOMAINS AS MODULATORS OF GENE EXPRESSION | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066410-A1 | INHIBITORS OF BROMODOMAINS AS MODULATORS OF GENE EXPRESSION | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-03-06 | — | — | US | disclosed |
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008055233-A1 | PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207632-A1 | PROTEIN KINASE INHIBITORS | ERBB3, ERBB2, AXL | KMT2A 624/4885MEN1 1002/4885MAPT 1472/4885 |
| US-20140066410-A1 | INHIBITORS OF BROMODOMAINS AS MODULATORS OF GENE EXPRESSION | NFKBIA, NFKB2, IKBKG | KMT2A 1147/4885MEN1 3799/4885MAPT 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.